JANET DIAZ: Open Payments
NPI 1639764368 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$228 in 10 payments from 9 companies in 2025. Trend: 2023 $134 · 2024 $501 · 2025 $228
Food & beverage: $228
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 2 | $37 |
| Merck Sharp & Dohme LLC | 1 | $30 |
| AstraZeneca Pharmaceuticals LP | 1 | $28 |
| ABBVIE INC. | 1 | $27 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Novartis Pharmaceuticals Corporation | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
Products named: KEYTRUDA, LYNPARZA, IMBRUVICA, XPOVIO, Nubeqa, ERLEADA, Xtandi, SCEMBLIX.
Industry payments across CA — which companies pay providers there.
